The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback